2-(2'-甲基苯基)哌啶 | 118576-99-1

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(2'-甲基苯基)哌啶
• 英文名称: 2-(2'-methylphenyl)piperidine
• 英文别名: 2-(o-tolyl)piperidine；2-(2-Methylphenyl)piperidine
• CAS: 118576-99-1
• 化学式: C₁₂H₁₇N
• mdl: MFCD02663599
• 分子量: 175.274
• InChiKey: QLDMVIFAIGYZPR-UHFFFAOYSA-N

物化性质

• 沸点：
  112-114 °C(Press: 12 Torr)
• 密度：
  0.9096 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2'-甲基苯基)哌啶 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 1-Methyl-2-o-tolyl-1-trimethylsilanylmethyl-piperidinium; iodide
  参考文献：
  名称：

  Rearrangement of 1-methyl-2-(substituted-phenyl)piperidinium 1-methylides in a neutral medium

  摘要：

  DOI：

  10.1021/jo00265a022
• 作为产物：
  描述：

  6-(o-tolyl)-2,3,4,5-tetrahydropyridine 在 甲基二乙氧基硅烷 、 diethylzinc 、 (S,S)-(+)-2,6-双[2-(羟基二苯甲基)-1-吡咯烷基-甲基]-4-甲基苯酚 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 48.0h， 以58%的产率得到2-(2'-甲基苯基)哌啶
  参考文献：
  名称：

  锌催化环亚胺的不对称氢化硅烷化：手性2-芳基取代的吡咯烷类药物的合成

  摘要：

  据报道，由手性锌配合物促进的环状亚胺的首次成功的对映选择性氢化硅烷化。原位生成的锌-苯酚锌与硅烷的络合物以高收率和优异的对映选择性（高达99％ee）提供了药学上对映体富集的对映体富集的2-芳基取代的吡咯烷。所提出方法的合成效用在相应手性环胺的有效合成中得到证明，所述手性环胺是阿替卡普特和拉罗替尼的药物前体。

  DOI：

  10.1002/adsc.202001043

文献信息

• [EN] BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES COMME INHIBITEURS DE PI3K/M TOR, MÉTHODES D'UTILISATION ET DE FABRICATION BENZOXAZEPINES AS INHIBITORS OF PI3K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：EXELIXIS INC

  公开号：WO2010138487A1

  公开（公告）日：2010-12-02

  The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK- transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer.

  这项发明涉及式(I)的化合物：该发明提供了抑制、调节和/或调节P13K和/或mTOR的化合物，这些化合物在治疗哺乳动物的高增殖性疾病，如癌症，方面非常有用。该发明还提供了制备该化合物的方法，以及在治疗哺乳动物，特别是人类的高增殖性疾病中使用这些化合物的方法，以及含有这些化合物的药物组合物。例如，对PI3fC-α mTOR或两者都具有活性有助于其病理学和/或症状学的癌症包括乳腺癌、套细胞淋巴瘤、肾细胞癌、急性髓细胞白血病、慢性髓细胞白血病、NPM/ALK转化的间变性大细胞淋巴瘤、弥漫性大B细胞淋巴瘤、横纹肌肉瘤、卵巢癌、子宫内膜癌、宫颈癌、非小细胞肺癌、小细胞肺癌、腺癌、结肠癌、直肠癌、胃癌、肝细胞癌、黑色素瘤、胰腺癌、前列腺癌、甲状腺癌、间变性大细胞淋巴瘤、血管瘤、胶质母细胞瘤或头颈癌。
• Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders
  申请人：Collantes Elizabeth Martha

  公开号：US20090197859A1

  公开（公告）日：2009-08-06

  The present invention relates to novel pyridinyl derivatives of Formula wherein Y, Z, L, R 1 through R 11 , n, m, p, q, t are as defined herein, that are 5-HT receptor ligands, particularly the 5-HT6 subtype, and as such are useful for treating diseases wherein modulation of 5-HT activity is desired. The present invention relates to novel pyridinyl derivatives including their pharmaceutically acceptable salts. The invention also relates to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating diseases of the central nervous system such as schizophrenia.

  本发明涉及一种新颖的吡啶基衍生物，其化学式如下所示：其中Y、Z、L、R1至R11、n、m、p、q、t的定义如本文所述，它们是5-HT受体配体，特别是5-HT6亚型，因此可用于治疗需要调节5-HT活性的疾病。本发明涉及包括其药用盐在内的新型吡啶基衍生物。该发明还涉及用于制备、制备中间体、含有这些化合物的药物组合物以及在治疗中枢神经系统疾病如精神分裂症中使用这些化合物的过程。
• Diversification of Unprotected Alicyclic Amines by C−H Bond Functionalization: Decarboxylative Alkylation of Transient Imines
  作者：Anirudra Paul、Jae Hyun Kim、Scott D. Daniel、Daniel Seidel

  DOI：10.1002/anie.202011641

  日期：2021.1.18

  efforts by many practitioners in the field, methods for the direct α‐C−H bond functionalization of unprotected alicyclic amines remain rare. A new advance in this area utilizes N‐lithiated alicyclic amines. These readily accessible intermediates are converted to transient imines through the action of a simple ketone oxidant, followed by alkylation with a β‐ketoacid under mild conditions to provide valuable

  尽管该领域的许多从业者做出了广泛的努力，但未受保护的脂环胺直接 α-C-H 键功能化的方法仍然很少。该领域的一项新进展是利用 N-锂化脂环胺。这些易于获得的中间体通过简单的酮氧化剂的作用转化为瞬时亚胺，然后在温和条件下用β-酮酸进行烷基化，以前所未有的轻松方式提供有价值的β-氨基酮。具有现有 α-取代基的底物可实现区域选择性 α'-烷基化。该方法还适用于通过加入SN Ar步骤方便地一锅合成多环二氢喹诺酮类药物。
• A Selenourea-Thiourea Brønsted Acid Catalyst Facilitates Asymmetric Conjugate Additions of Amines to α,β-Unsaturated Esters
  作者：Yingfu Lin、William J. Hirschi、Anuj Kunadia、Anirudra Paul、Ion Ghiviriga、Khalil A. Abboud、Rachael W. Karugu、Mathew J. Vetticatt、Jennifer S. Hirschi、Daniel Seidel

  DOI：10.1021/jacs.9b12457

  日期：2020.3.25

  enantioselectivity via the conjugate addition of cyclic amines to unactivated α,β-unsaturated esters. A related strategy enables the kinetic resolution of racemic cyclic 2-arylamines, using benzyl acrylate as the resolving agent. Reactions are facilitated by an unprecedented selenourea-thiourea organocatalyst. As elucidated by DFT calculations and 13C kinetic isotope effects studies, the rate-limiting and enantiodetermining

  通过将环胺与未活化的 α,β-不饱和酯共轭加成，可以获得具有高水平对映选择性的 β-氨基酯。使用丙烯酸苄酯作为拆分剂，相关策略能够实现外消旋环状 2-芳胺的动力学拆分。前所未有的硒脲-硫脲有机催化剂促进了反应。通过 DFT 计算和 13C 动力学同位素效应研究阐明，反应的限速和对映体决定步骤是催化剂对两性离子中间体的质子化。这是一种罕见的情况，其中硫脲化合物充当不对称布朗斯台德酸催化剂。
• Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
  申请人：Aay Naing

  公开号：US20120258953A1

  公开（公告）日：2012-10-11

  The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK-transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer.

  本发明涉及化合物I式的化合物：本发明提供了一种抑制、调节和/或调节P13K和/或mTOR的化合物，其在哺乳动物中治疗增殖过度性疾病，如癌症方面非常有用。本发明还提供了制备该化合物的方法，使用这些化合物在哺乳动物中治疗增殖过度性疾病的方法，特别是人类，并提供了包含这些化合物的制药组合物。例如，对于活性针对PI3fC-alph mTOR或两者都对其病理和/或症状学产生贡献的癌症，包括乳腺癌、曼托细胞淋巴瘤、肾细胞癌、急性髓性白血病、慢性髓性白血病、NPM / ALK转化的间变性大细胞淋巴瘤、弥漫性大B细胞淋巴瘤、横纹肌肉瘤、卵巢癌、子宫内膜癌、宫颈癌、非小细胞肺癌、小细胞肺癌、腺癌、结肠癌、直肠癌、胃癌、肝细胞癌、黑色素瘤、胰腺癌、前列腺癌、甲状腺癌、间变性大细胞淋巴瘤、血管瘤、胶质母细胞瘤或头颈癌。